Plain-English translation of NCT06693830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new blood test called PhasED-seq that looks for cancer cells in your blood during lymphoma treatment. The goal is to see if doctors can safely reduce chemotherapy doses for patients whose cancer disappears early, based on what the blood test shows.
Standard lymphoma treatment requires all patients to complete the same number of chemotherapy cycles, even if their cancer is gone early. This trial hopes to show that some patients could skip the final chemotherapy doses and receive a gentler treatment instead, if the blood test confirms their cancer is gone.
You likely qualify if…
You likely don't qualify if…
You will receive standard chemotherapy for the first four treatment cycles. Blood samples will be drawn and tested with the new blood test after your third cycle. If the blood test shows no cancer cells and your imaging scans look good, you will skip chemotherapy for your last two cycles and receive a gentler antibody treatment alone instead. If the blood test shows cancer is still present or the test wasn't successful, you will continue with standard chemotherapy for all six cycles as planned.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States